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B
esides its actions in the maintenance of normal renal function and blood pressure, the renal dopaminergic system has remarkable effects in the regulation of inflammatory reaction and tissue injury. 1, 2 In mice, intrarenal dopamine deficiency leads to increased infiltration of inflammatory cells and oxidative stress. 3 Conversely, increased intrarenal dopamine prevents the increase in the expression of profibrotic pathways and decreases glomerular and tubular interstitial injury resulting from chronic angiotensin II (Ang II) infusion. 4 In diabetic mice, increased intrarenal dopamine levels decreased markers of oxidative stress, inhibited macrophage infiltration, and reduced renal damage, whereas decreased intrarenal dopamine production had the opposite effect. 5 The protective effects of dopamine on the development of renal inflammation and tissue damage are mediated, at least in part, by the dopamine D2 receptor (D 2 R) that acts as a negative regulator of inflammation. 1, 6 Mice with lack or reduced level of D 2 R expression and function in the kidney have increased renal expression of proinflammatory and decreased the expression of anti-inflammatory cytokines/chemokines, as well as histological and functional evidence of renal inflammation and injury, indicating that impaired function of the D 2 R results in renal inflammation and organ damage. 1 The protective effects of D 2 R are not restricted to renal inflammation. Lack of D 2 R expression in astrocytes results in a marked inflammation in multiple brain regions and treatment of DRD2 wild-type (WT) mice with a selective D 2 R agonist partially suppressed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-mediated inflammation in nigral dopaminergic neurons. 7 In humans, the DRD2 gene is highly polymorphic. The presence of some common single nucleotide polymorphisms (SNPs; rs6276, rs6277, and rs1800497) in the DRD2 gene results in decreased D 2 R expression and function attributable to decreased D 2 R mRNA stability and synthesis of the receptor and are associated with elevated blood pressure and even hypertension. 6, 8, 9 We have shown that renal proximal tubule cells (RPTCs) of subjects bearing these SNPs have decreased the expression of the D 2 R, express a proinflammatory phenotype with increased TNFα, cytokines, and chemokines and a profibrotic phenotype with increased TGFβ1, markers of epithelial mesenchymal transition (EMT), such as vimentin and snail, and synthesize the extracellular matrix proteins collagen 1a (Col1a) and fibronectin 1 (FN1). 6 These alterations were reproduced when RPTCs carrying the DRD2 WT gene were treated with TGFβ1. 6 These results suggest that subjects bearing these D 2 R SNPS may have increased susceptibility to chronic kidney disease. Consistent with our data, a study in an Asian Indian population with type 2 diabetes mellitus found that a D 2 R polymorphism (rs1799732) resulting in decreased expression of the receptor conferred susceptibility to chronic diabetic nephropathy. 10 Micro-RNAs (miRNAs) are short single-stranded RNAs that post-transcriptionally repress gene expression via degradation or translational inhibition of their target mRNAs. Several miRNAs are associated with the regulation of chemokines, fibrosis, extracellular matrix remodeling, and cell adhesion. 11, 12 We hypothesized that regulation of miRNA expression is one of the mechanisms involved in the protective effects of D 2 R. To test this hypothesis, we studied miRNA expression in RPTCs with or without D 2 R SNPs.
Materials and Methods

Cells
RPTCs were isolated from human kidney specimens from patients who had unilateral nephrectomy because of renal carcinoma or trauma. Only the visually and histologically normal pole, distal from the affected part of the kidney, was used to isolate RPTCs and immortalized, as previously described. 13 A University of Virginia Institutional Review Board-approved protocol was used according to the Declaration of Helsinki. The RPTCs were genotyped for the presence of rs6276, rs6277, and rs1800497 SNPs. Four cell lines from subjects not carrying SNPs (D 2 R-WT), 3 from subjects bearing rs6276 and rs6277 alleles, and 2 from subjects bearing rs6276 and rs1800497 alleles were studied. These 3 SNPs occur within and adjacent to the DRD2 gene and because of their close proximity are likely to be in linkage disequilibrium, which limits the possibility of identifying cell lines bearing only one of the SNPs. The cell lines carrying SNPs were termed RPTC-D 2 R-SNPs and those not carrying SNPs were called RPTC-D 2 R-WT. These quences, chromosomal loci, and frequencies of these D 2 R-SNPs are shown in Table S1 and Figure S1 in the online-only Data Supplement.
Transfections and Assays
Cells were studied untransfected and transfected with plasmid harboring human DRD2 WT, miScript miRNA mimics, inhibitors targeting hsa-miR-217 or hsa-miR-224-5p, or siRNA targeting human DRD2 or Ror2 as described in Methods in the online-only Data Supplement.
Cells were collected and lysates were prepared for purification of miRNA and total RNA for miRNA expression profiling and quantitative real-time polymerase chain reaction (PCR) as described in Methods in the online-only Data Supplement and Table S2 . Cell lysates were also prepared for protein extraction and immunoblotting (Methods in the online-only Data Supplement)
miRNA Expression Profiling
The miRNA expression profiling in human RPTCs in both groups was performed using a human miScript miRNA PCR Array (SABiosciences-Qiagen), which profiles the expression of the 372 most abundantly expressed miRNAs. Real-time PCR was performed following the manufacturer's protocol. Quality controls were all within the recommended range, and the data were analyzed using the manufacturer's software.
Immunofluorescence and Confocal Microscopy
Human RPTCs, grown on poly-d-lysine-coated coverslips to 50% to 70% confluence, were immunostained using a rabbit polyclonal 
Statistical Analysis
The data are expressed as mean±SEM. Comparisons between 2 groups used the Student t test. One-way factorial ANOVA followed by Holm-Sidak test was used to assess significant differences in >2 groups. P<0.05 was considered significant.
Results
Presence of D 2 R SNPs Increases Expression of TGFβ1 and Its Target Genes in Human RPTCs
The expression of D 2 R mRNA was lower in RPTC-D 2 R-SNPs than in RPTC-D 2 R-WT ( Figure 1A ), in agreement with our previous report. 6 Because the degree of reduction in D 2 R expression was similar in RPTCs bearing the rs6276 and rs6277 alleles and those bearing the rs6276 and rs1800497 alleles, 6 the samples were pooled for further analysis. The mRNA expression of TGFβ1 and the EMT markers matrix metalloproteinase (MMP)-3, FN1, and Col1a was increased in RPTC-D 2 R-SNPs than in RPTC-D 2 R-WT ( Figure 1A ). Decreasing D 2 R expression in RPTC-D 2 R-WT with DRD2 siRNA downregulated D 2 R mRNA and protein ( Figure S2 ) and increased the expression of TGFβ1, MMP3, FN1, and Col1a ( Figure 1B) . Conversely, increasing D 2 R expression in RTPC-D 2 R-SNPs by transfection of a DRD2 plasmid which increased D 2 R mRNA expression and protein ( Figure S2 ) decreased the mRNA expression of TGFβ1, MMP3, FN1, and Col1a ( Figure 1C ). These effects are observed in the absence of ligand added to the medium because both RPTCs and microdissected proximal tubules, in culture, produce significant amounts of dopamine from levodopa present in the serum 
Several miRNAs Are Differentially Expressed in RPTC-D 2 R-SNPs
To determine the mechanism underlying the effects of the D 2 R SNPs, we studied the expression of miRNAs that are associated with the transcriptional regulation of target genes. The expression of 372 miRNAs was analyzed in RPTC-D 2 R-WT and RPTC-D 2 R-SNPs using a qunatitative reverse transcriptase-PCR array. Fifty miRNAs were differentially expressed by >2-fold in RPTC-D 2 R-SNPs in comparison with RPTC-D 2 R-WT; 36 miRNAs were downregulated and 14 were upregulated (Table S3 ). The expressions of 4 miRNAs (miR-217, miR-224-5p, miR-335-5p, and miR-1265) were downregulated >4-fold and that of 1 miRNA (miR-1290) was upregulated also >4-fold in RPTC-D 2 R-SNPs than in RPTC-D 2 R-WT. These miRNAs were selected for further experiments.
D 2 R Function Regulates the Expression of miR-217 and miR-224-5p
The decreased expression of miR-217 (Figure 2A ), miR-224-5p ( Figure 2B ), miR-335-5p ( Figure 2C ), and miR-1265 ( Figure 2D ) and increased expression of miR-1290 ( Figure 2E ) Figure 3A-3F ), but had no effect in RPTC-D 2 R-SNPs ( Figure 3A-3E) , probably because miR-217 is already decreased in RPTC-D 2 R-SNPs (Figure 2A ; Table S3 ).
By contrast, treatment of RPTC-D 2 R-WT or RPTC-D 2 RSNPs with miR-224-5p mimic or inhibitor had no significant effect on TGFβ1 and EMT markers ( Figure S4 ) although the mimic increased miR-224-5p and the inhibitor decreased miR-224-5p expression ( Figure S3 ). These results indicate 
Wnt5a Mediates the miR-217 Effects on TGFβ1 and EMT Markers
To elucidate the mechanism by which miR-217 regulates the expression of TGFβ1 and its target genes, we used TargetScanHuman6.2 to predict miR-217 targets. This analysis showed Wnt5a as one of the targets of miR-217. Consistent with the decreased miR-217 expression in RPTC-D 2 R-SNPs in comparison with RPTC-D 2 R-WT, we found increased Wnt5a mRNA and protein expression in RPTC-D 2 R-SNPs. In RPTC-D 2 R-WT, treatment with miR-217 mimic decreased whereas miR-217 inhibitor increased Wnt5a mRNA and protein expression ( Figure 4A and 4B) . In RPTC-D 2 R-SNPs, miR-217 mimic also decreased the mRNA and protein expression of Wnt5a but transfection of miR-217 inhibitor had no significant effect ( Figure 4A and 4B), similar to those obtained for TGFβ1 and EMT markers, probably because the expression of miR-217 is already decreased in these cells (Figure 2A ; Table  S3 ), as indicated earlier. These results indicate that Wnt5a is negatively regulated by miR-217.
To determine whether Wnt5a mediates the inhibitory effects of miR-217 on TGFβ1, we treated RPTC-D 2 R-WT with human recombinant Wnt5a and determined the expression of TGFβ1. Both mRNA and protein expressions of TGFβ1 were increased in cells treated with Wnt5a ( Figure 5A ). Wnt5a signals although the receptor tyrosine kinase-like orphan receptor 2 (Ror2) activating the noncanonical Wnt pathway. 16 In RPTC-D 2 R-WT, the mRNA expression of Ror2 was increased by treatment with Wnt5a and decreased by treatment with Ror2 siRNA; treatment with both Wnt5a and Ror2 siRNA blunted the increase in Ror2 expression elicited by Wnt5a demonstrating that Wnt5a positively regulates the expression of Ror2 ( Figure 5A ). Silencing Ror2 decreased TGFβ1 expression and blunted significantly the increase induced by treatment with Wnt5a ( Figure 5A ). In RPTC-D 2 R-SNPs, which have increased the expression of Wnt5a silencing Ror2 decreased the expression of both Ror2 and TGFβ1 ( Figure 5B ), indicating that the stimulatory effect of D 2 R SNPs on TGFβ1 is mediated by the Wnt5a-Ror2 pathway.
Discussion
These results show that in human RPTCs, the presence of common allelic variants (SNPs rs6276, rs6277, and rs800497) in the D 2 R that decrease its expression and function results in increased expression of TGFβ1 and an EMT phenotype. This phenotype is mimicked by silencing D 2 R in RPTCs bearing D 2 R-WT and reversed by rescuing D 2 R expression in RPTCs with D 2 R-SNPs, indicating that the D 2 R has protective effects in these cells. We show that the protective effects of the D 2 R are mediated by regulation of miR-217 expression, as D 2 R downregulation decreases miR-217 expression, whereas D 2 R overexpression has the opposite effect. A decrease in miR-217 expression or the inhibition of its function increases the expression of TGFβ1 and EMT markers. This is mediated by releasing the repressor effect of miR-217 on Wnt5a and its receptor Ror2 (Figure 6 ). miRNAs may induce or protect from fibrosis by targeting TGFβ or its downstream pathways. 17 Of the 5 miRNAs that were up-or downregulated >4-fold in RPTC-D 2 R -SNPs only miR-217 and miR-224-5p were directly regulated by the D 2 R and only miR-217 negatively regulated TGFβ1 and EMT markers. miR-217 has been shown to have a role in the development and progression of renal fibrosis. In patients with chronic kidney disease, the degree of tubulointerstitial fibrosis and proteinuria, but not glomerulosclerosis, negatively correlated with the amount of urinary miR-217 that is derived most likely from tubular epithelial cells and podocytes. 18 Chronic pancreatitis and pancreatic cancer tissues demonstrated active EMT process and decreased miR-217 expression, whereas ectopic expression of miR-217 inhibited TGFβ1-induced EMT. 19 However, miRNAs may have a cell type-specific pattern of expression and in human liver cancer tissues an EMT phenotype was associated with increased expression of miR-216a/217 and overexpression of miR-216a/217 in hepatic cancer cells induced EMT by activating the TGFβ and PI3K/AKT signaling pathways through downregulation of PTEN (phosphatase and tensin homolog) and SMAD7 (Drosophila mothers against decapentaplegic homolog 7) . 20 In mouse mesangial cells treated with TGFβ and in the glomeruli of diabetic mice, miR-216a/miR-217 cluster levels were increased and mediated the downstream effects of TGFβ including the expression of genes related to production of extracellular matrix. 21 In RPTC-D 2 R-SNPs, miR-216a was not consistently changed, indicating species and cell-type differences in the regulation of these miRNAs.
Wnt5a is a member of the Wnt family of secreted glycoproteins that play important roles in development, cell proliferation, and cell migration. A major receptor for Wnt5a is Ror2, which mediates Wnt5a cellular functions through the noncanonical Wnt pathway. 16 Most studies on the role of the Wnt5a-Ror2 pathway have been performed in cancer cells in which upregulation of the pathway either promotes tumor formation and progression or acts as a tumor suppressor depending on the cell type. 22 The noncanonical Wnt5a pathway has been implicated in the molecular mechanisms underlying TGFβ-induced expression of extracellular matrix in airway smooth muscle cells. 23 Other studies have also implicated Wnt5a expression and signaling in renal and hepatic fibrosis. 24, 25 Wnt5a increases the proliferation and viability of fibroblasts in the lungs of patients with interstitial pneumonia. 26 In epithelial Madin-Darby canine kidney cells undergoing EMT, Wnt5a expression was elevated and transient Wnt5a silencing attenuated both cell migration and invasion in these cells. 27 Moreover, Wnt5a and Ror2 are induced in kidneys after unilateral ureteral obstruction, where Ror2 was expressed in tubular epithelial cells exhibiting EMT characteristics. 24 Our results show that the increase in TGFβ1 in human RPTCs with D 2 R SNPs is mediated by the miR-217-Wnt5a-Ror2 pathway.
miRNAs that are located in intergenic regions, such as miR-217, carry their own promoters. One possible mechanism of the regulation of miR-217 expression by the D 2 R is through regulation of transcription factors binding to the miR-217 promoter. Nurr1 is a nuclear receptor transcription factor belonging to the NR4A family of orphan nuclear receptors and functions as a constitutively active transcription factor. Gene expression profiling of cells overexpressing Nurr1 has shown that miR-217 is a target of Nurr1. 28 The D 2 R interacts with Nurr1 via ERK signaling and is critical for its transcription. 29 The deletion of D 2 R in dopaminergic neurons results in decreased Nurr1 expression. 29 Preliminary data from our laboratory show that decreasing D 2 R expression selectively in the mouse kidney also reduces renal cortical Nurr1 expression. Thus, the presence of allelic variants of the D 2 R that reduces its expression and function may also decrease Nurr1 expression, which in turn decreases miR-217 transcription. Experiments to test this possibility are currently being performed.
Perspectives
Genetic factors contribute to the susceptibility to renal disease associated with essential hypertension, and hypertension may cause progressive kidney disease only in genetically susceptible individuals. 30, 31 The genetic predisposition to chronic kidney disease is polygenic, but to date only a few genes have been shown to be contributory. [32] [33] [34] These results show that RPTCs from human subjects carrying common DRD2 allelic variants that are associated with hypertension and result in decreased dopamine D 2 R mRNA and protein expression have increased TGFβ1, a profibrotic phenotype, and markers of EMT that are mediated by the miR-217-Wnt5a-Ror2 pathway. Individuals carrying these D 2 R allelic variants could be more vulnerable to renal injury. Genetic testing can help to identify the individuals at risk and pharmacological treatment tailored to prevent or ameliorate the insult may decrease the prevalence of renal injury and chronic kidney disease.
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What Is New?
• We show that the increased transforming growth factor β1 expression and markers of epithelial mesenchymal transition in renal proximal tubule cells from individuals carrying polymorphisms of the dopamine D2 receptor that downregulate its expression are mediated by activation of the miR-217-Wnt5a-Ror2 pathway.
What Is Relevant?
• Individuals carrying these dopamine D2 receptor single nucleotide polymorphisms could be more vulnerable to renal injury when challenged with an insult, such as hypertension. Genetic testing can help to identify the individuals at risk and pharmacological treatment targeting miR-217-Wnt5a-Ror2 pathway tailored to prevent or ameliorate the insult could decrease the prevalence of renal injury and chronic kidney disease. 
Cell culture
Immortalized RPTCs were kept at 37 °C in an atmosphere containing 5% CO 2 and cultured to 90-95% confluence in non-polarizing conditions in DMEM-F12 containing (final concentrations): plasmocin (2.5μg/ml, Fisher Scientific ); EGF (10ng/ml, Sigma), dexamethasone (36ng/ml, Sigma), triiodothyronine (2ng/ml; Sigma), insulin-transferrinselenium (ITS, 1X, Invitrogen); penicillin/streptomycin (1X, Invitrogen); fetal bovine serum (2%, Invitrogen); and G418 (0.4%, EMD Chemicals) (1)
Transfections
Transfection with human DRD2 plasmid RPTCs carrying D 2 R SNPs were transfected with an empty vector or plasmid harboring wild-type human DRD2 under the control of CMV promoter (RC202476, Origene Technologies, Inc.), using FuGene HD transfection reagent (E2311; Promega Corporation) as per the manufacturer's guidelines. Briefly, 4μg of plasmid DNA were dissolved in 400μl with serum-free medium and mixed with 16μl of FuGene HD transfection. The transfection complex was incubated for 15minutes at room temperature and added drop wise onto the cells in 10 cm tissue culture plates. Three days following transfection, the RPTCs were harvested for protein extraction and immunoblotting, total RNA preparation and RT-qPCR, or processed for Immunofluorescence staining. Transfection efficiency was 40-45%.
Transient transfection of miRNA mimic or inhibitor
Human RPTCs were plated in 6-well plates at 2×10 5 cells per well one day before treatment. Predesigned miScript miRNA mimics or inhibitors targeting hsa-miR-217 or hsa-miR-224-5p were transfected (8nM for mimics and 50nM for inhibitors) into the RPTCs using HiperFect (Qiagen), according to the manufacturer's instructions. AllStars siRNA and miScript inhibitor negative control (Qiagen, Valencia, CA) were transfected as controls. Two days after transfection, the RPTCs were harvested for extraction of protein (for immunoblotting) and total RNA and miRNA (for quantitative real-time PCR), or processed for immunofluorescence staining.
RNA interference (siRNA)
Human RPTCs were plated in 6-well plates at 2×10 5 cells per well one day before treatment. Predesigned siRNA (Qiagen) targeting human DRD2 or Ror2 mRNA was transfected (25nM, 48h) into human RPTCs using HiperFect according to the manufacturer's instructions. AllStars siRNA (25nM, 48h; Qiagen) served as negative control (non-silencing siRNA). For RPTCs treated with Wnt5a and Ror2 siRNA, RPTCs were treated with Ror2 siRNA (25nM) or non-silencing siRNA (25nM) for 48h, then treated with recombinant human/mouse Wnt5a (400 ng/ml: R&D, Minneapolis, MN) or vehicle in serum-free DMEM/F12 medium for 18h. After treatment, the cells were harvested for protein and mRNA extraction. 
